New antibiotic dosing method could cut infections after heart surgery
NCT ID NCT07658378
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two ways of giving the antibiotic cefazolin during coronary artery bypass surgery to prevent wound infections. One group gets the drug as a steady drip (continuous infusion), the other as standard short injections. The trial will enroll 100 adults in Egypt and track how many develop a surgical site infection. If the continuous method works better, it could change how antibiotics are given during heart surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cefazolin
- What this could lead to
- If continuous infusion works better, it could become a new standard to prevent infections after heart bypass surgery.
- What could go wrong
- This is a small, early-phase trial in one country, so results may not apply everywhere. The difference between the two methods may be small or not meaningful.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Cardiothoracic ICU-admitted patients who underwent CABG on CPB. Exclusion Criteria: * Patients who require reoperation within 30 days. * Immunosuppressant patients. * Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively. * Pregnancy or breastfeeding. * Patients who refused to sign the informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Surgical site infection (SSI) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Probiotic secretions take aim at MRSA's armor in wound infections
- A simple drain may slash wound infections after gynecologic cancer surgery
- Drone Warfare's hidden toll: new study tracks infection risk in combat wounds
- Vacuum bandage may shield ECMO patients from wound infections
- Wound injection may slash infection risk in emergency abdominal surgery
- New rinse aims to cut infection risk in spine surgery